- Bacterial Infections 101 Pictures Slideshow
- Take the Tummy Trouble Quiz
- Hepatitis C Slideshow Pictures
Does Avelox (moxifloxacin) cause side effects?
Avelox (moxifloxacin) is a fluoroquinolone antibiotic used to treat infections caused by gram-positive and gram-negative bacteria like Streptococcus anginosus, Streptococcus constellatus, Streptococcus pneumonia, Enterobacter cloacae, Escherichia coli, Haemophilus influenza, Klebsiella pneumonia, Moraxella catarrhalis, Clostridium perfringens, Chlamydophila pneumonia, and Mycoplasma pneumonia.
Avelox works by blocking DNA gyrase enzyme, which is responsible for production and repair of bacterial DNA. Blocking of DNA gyrase leads to bacteria death and prevents worsening of infection.
Common side effects of Avelox include
Serious side effects of Avelox include
- seizures in patients with central nervous system diseases,
- tendinitis and even rupture of tendons (particularly the Achilles tendon),
- worsened muscle weakness in individuals with myasthenia gravis,
- worsened low blood glucose levels when combined with sulfonylureas,
- allergic reactions such as hives and anaphylaxis (rare), and
- inflammation of the colon such as C. difficile or pseudomembranous colitis (symptoms include diarrhea, fever, abdominal pain, and possibly shock).
Drug interactions of Avelox include aluminum and magnesium containing antacids, sucralfate, and multivitamins, because they can lower absorption of Avelox and reduce its effectiveness. They should be administered 4 hours before or 8 hours after Avelox.
What are the important side effects of Avelox (moxifloxacin)?
Side effects of moxifloxacin are
Rare allergic reactions have been described, such as hives and anaphylaxis (shock). Moxifloxacin should be used with caution in patients with central nervous system diseases such as seizures, because rare seizures have been reported in patients receiving moxifloxacin.
Moxifloxacin should be avoided in children and adolescents less than 18 years of age, as safe use in these patients has not been established.
Moxifloxacin as well as other antibiotics in the fluoroquinolone class of antibiotics, has been associated with tendinitis and even rupture of tendons, particularly the Achilles tendon. This risk is especially increased in patients over 60 or patients taking corticosteroids ( for example prednisone).
Many antibiotics, including moxifloxacin, can alter the normal bacteria in the colon and encourage overgrowth of a bacterium responsible for the development of inflammation of the colon, (C. difficile or pseudomembranous colitis).
Fluoroquinolones have neuromuscular blocking activity and can worsen muscles weakness in individuals with myasthenia gravis. They also worsen low blood glucose levels when combined with sulfonylureas (for example, glyburide [Micronase, Diabeta, Glynase, Prestab]).
Avelox (moxifloxacin) side effects list for healthcare professionals
The following serious and otherwise important adverse reactions are discussed in greater detail in the product labeling:
- Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects
- Tendinitis and Tendon Rupture
- Peripheral Neuropathy
- Central Nervous System Effects
- Exacerbation of Myasthenia Gravis
- QT Prolongation
- Other Serious and Sometimes Fatal Adverse Reactions
- Hypersensitivity Reactions
- Clostridium difficile-Associated Diarrhea
- Blood Glucose Disturbances
- Development of Drug Resistant Bacteria
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to Avelox in 14981 patients in 71 active controlled Phase II-IV clinical trials in different indications.
- The population studied had a mean age of 50 years (approximately 73% of the population was less than 65 years of age), 50% were male, 63% were Caucasian, 12% were Asian and 9% were Black.
- Patients received Avelox 400 mg once daily oral, intravenous, or sequentially (intravenous followed by oral).
- Treatment duration was usually 6 to 10 days, and the mean number of days on therapy was 9 days.
- Discontinuation of Avelox due to adverse reactions occurred in 5% of patients overall, 4% of patients treated with 400 mg PO, 4% with 400 mg intravenous and 8% with sequential therapy 400 mg oral/intravenous.
- The most common adverse reactions ( > 0.3%) leading to discontinuation with the 400 mg oral doses were nausea, diarrhea, dizziness, and vomiting.
- The most common adverse reaction leading to discontinuation with the 400 mg intravenous dose was rash. The most common adverse reactions leading to discontinuation with the 400 mg intravenous/oral sequential dose were diarrhea, pyrexia.
- Adverse reactions occurring in 1% of Avelox-treated patients and less common adverse reactions, occurring in 0.1 to 1% of Avelox-treated patients, are shown in Tables 2 and Table 3, respectively.
- The most common adverse drug reactions (3%) are nausea, diarrhea, headache, and dizziness.
Table 2: Common (1% or more) Adverse Reactions Reported in Active-Controlled Clinical Trials with Avelox
|System Organ Class||Adverse Reactions||% (N=14,981)|
|Blood and Lymphatic System Disorders||Anemia||1|
|General Disorders and Administration Site Conditions||Pyrexia||1|
|Investigations||Alanine aminotransferase increased||1|
|Metabolism and Nutritional Disorder||Hypokalemia||1|
|Nervous System Disorders||Headache||4|
Table 3: Less Common (0.1 to less than 1%) Adverse Reactions Reported in Active-Controlled Clinical Trials with AVELOX (N=14,981)
|System Organ Class||Adverse Reactions|
|Blood and Lymphatic System Disorders||Thrombocythemia|
|Cardiac Disorders||Atrial fibrillation|
|Ear and Labyrinth Disorders||Vertigo Tinnitus|
|Eye Disorders||Vision blurred|
|Gastrointestinal Disorders||Dry mouth|
Gastroesophageal reflux disease
|General Disorders and Administration Site Conditions|
|Hepatobiliary disorders||Hepatic function abnormal|
|Infections and Infestations||Candidiasis|
|Investigations||Aspartate aminotransferase increased|
Blood alkaline phosphatase increased Electrocardiogram
Blood lactate dehydrogenase increased
Blood amylase increased
Blood creatinine increased
Blood urea increased
Prothrombin time prolonged
Eosinophil count increased
Activated partial thromboplastin time prolonged
Blood triglycerides increased
Blood uric acid increased
|Metabolism and Nutrition Disorders||Hyperglycemia|
|Musculoskeletal and Connective Tissue Disorders||Back pain|
Pain in extremity
|Nervous System Disorders||Dysgeusia|
|Renal and Urinary Disorders||Renal failure|
|Reproductive System and Breast Disorders||Vulvovaginal pruritus|
|Respiratory, Thoracic, and Mediastinal Disorders||Dyspnea|
|Skin and Subcutaneous Tissue||Rash|
Changes in laboratory parameters, which are not listed above and which occurred in 2% or more of patients and at an incidence greater than in controls included: increases in mean corpuscular hemoglobin (MCH), neutrophils, white blood cells (WBCs), prothrombin time (PT) ratio, ionized calcium, chloride, albumin, globulin, bilirubin; decreases in hemoglobin, red blood cells (RBCs), neutrophils, eosinophils, basophils, glucose, oxygen partial pressure (Po2), bilirubin, and amylase.
It cannot be determined if any of the above laboratory abnormalities were caused by the drug or the underlying condition being treated.
Table 4 below lists adverse reactions that have been identified during post-approval use of Avelox. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Table 4: Postmarketing Reports of Adverse Drug Reactions
|System Organ Class||Adverse Reactions|
|Blood and Lymphatic System Disorders||Agranulocytosis Pancytopenia|
|Cardiac Disorders||Ventricular tachyarrhythmias (including in very rare cases cardiac arrest and torsade de pointes, and usually in patients with concurrent severe underlying proarrhythmic conditions)|
|Ear and Labyrinth Disorders||Hearing impairment, including deafness(reversible in majority of cases)|
|Eye Disorders||Vision loss (especially in the course of CNS reactions, transient in majority of cases)|
|Hepatobiliary Disorders||Hepatitis (predominantly cholestatic) Hepatic failure (including fatal cases) Jaundice Acute hepatic necrosis|
|Immune System Disorders||Anaphylactic reaction Anaphylactic shock Angioedema (including laryngeal edema)|
|Musculoskeletal and Connective Tissue Disorders||Tendon rupture|
|Nervous System Disorders||Altered coordination, abnormal gait, muscle weakness, peripheral neuropathy (that may be irreversible), polyneuropathy|
|Psychiatric Disorders||Psychotic reaction (very rarely culminating in self-injurious behavior, such as suicidal ideation/thoughts or suicide attempts|
|Renal and Urinary Disorders||Interstitial nephritis|
|Respiratory, Thoracic and Mediastinal Disorders||Allergic pneumonitis|
|Skin and Subcutaneous Tissue Disorders||Photosensitivity/phototoxicity reaction Stevens-Johnson syndrome, toxic epidermal necrolysis|
What drugs interact with Avelox (moxifloxacin)?
Antacids, Sucralfate, Multivitamins And Other Products Containing Multivalent Cations
- Fluoroquinolones, including Avelox, form chelates with alkaline earth and transition metal cations.
- Oral administration of Avelox with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of Avelox, resulting in systemic concentrations considerably lower than desired.
- Therefore, Avelox should be taken at least 4 hours before or 8 hours after these agents.
- Fluoroquinolones, including Avelox, have been reported to enhance the anticoagulant effects of warfarin or its derivatives in the patient population.
- In addition, infectious disease and its accompanying inflammatory process, age, and general status of the patient are risk factors for increased anticoagulant activity.
- Therefore the prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if Avelox is administered concomitantly with warfarin or its derivatives.
- Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with fluoroquinolones, including Avelox, and an antidiabetic agent.
- Therefore, careful monitoring of blood glucose is recommended when these agents are coadministered.
- If a hypoglycemic reaction occurs, Avelox should be discontinued and appropriate therapy should be initiated immediately.
Nonsteroidal Anti-Inflammatory Drugs
- The concomitant administration of a nonsteroidal anti-inflammatory drug (NSAID) with a fluoroquinolone, including Avelox, may increase the risks of CNS stimulation and convulsions.
Drugs That Prolong QT
- There is limited information available on the potential for a pharmacodynamic interaction in humans between Avelox and other drugs that prolong the QTc interval of the electrocardiogram.
- Sotalol, a Class III antiarrhythmic, has been shown to further increase the QTc interval when combined with high doses of intravenous Avelox in dogs.
- Therefore, Avelox should be avoided with Class IA and Class III antiarrhythmics.
Multimedia: Slideshows, Images & Quizzes
Sore Throat or Strep Throat? How to Tell the Difference
Is this a sore throat or could it be strep throat? Your medical care depends on knowing if you have a viral infection or a...
Strep (Streptococcal) Throat Infection Quiz: Test Your Infectious Disease IQ
Take the Strep (Streptococcal) Throat Infection Quiz to learn about causes, symptoms, treatments, prevention methods, diagnosis,...
Picture of Strep Throat
Strep infection often produces a distinct pattern of white patches in the throat and on the tonsils, as well as red swollen...
Related Disease Conditions
Group B Strep
Group B strep are bacteria called Streptococcus agalactiae that may sometimes cause infections both in a pregnant woman and her baby. Symptoms include fever, seizures, heart rate abnormalities, breathing problems, and fussiness. Intravenous antibiotics are used to treat group B strep infections.
Is Strep Throat Contagious?
Strep throat is caused by group A streptococcus bacteria. Incubation period for strep throat is 1-5 days after exposure. If strep throat is treated with antibiotics, it is no longer contagious after 24 hours; if it is not treated with antibiotics, it is contagious for 2-3 weeks. Symptoms include fever, sore throat, tonsillitis, white spots or patches on the tonsils, and nausea and vomiting. Diagnosis of strep throat is performed through a rapid strep test.
Strep throat is a bacterial infection of the throat. Signs and symptoms of strep throat include headache, nausea, vomiting, sore throat, and fever. Strep throat symptoms in infants and children are different than in adults. Strep throat is contagious and is generally passed from person-to-person. Treatment for strep throat symptoms include home remedies and OTC medication; however, the only cure for strep throat are antibiotics.
Group A streptococcal infections are caused by group A Streptococcus, a bacteria that causes a variety of health problems, including strep throat, impetigo, cellulitis, erysipelas, and scarlet fever. There are more than 10 million group A strep infections each year.
Is E. coli Contagious? (Symptoms and Cure)
E. coli is an infection found worldwide. There are several subtypes of the E. coli species. E. coli spreads from person to person via contaminated food or water. Symptoms and signs of E. coli infection include diarrhea, stomach cramps, and sometimes fever. Antibiotics treat E. coli infection.
Second Source article from Government
Group A Streptococcal Infections
Second Source article from Government
Treatment & Diagnosis
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.